GAT211 is a positive allosteric modulator (PAM) of cannabinoid CB1 receptor signaling. GAT211 was found to amplify the therapeutic effect of endocannabinoids without the negative side effects of psychoactivity or tolerance. GAT211 caused a CB1-dependent suppression of paclitaxel-induced mechanical and cold allodynia with no sign of tolerance over 19 days of administration.